When was Viewpoint Molecular Targeting founded?

Viewpoint Molecular Targeting was founded in 2008 and raised its 1st funding round 6 years after it was founded.

Where is Viewpoint Molecular Targeting located?

Viewpoint Molecular Targeting is headquartered in Coralville, United States. It is registered at 2500 Crosspark Rd Coralville, IA 52241.

How many employees does Viewpoint Molecular Targeting have?

As of Jul 31, 2026, the latest employee count at Viewpoint Molecular Targeting is 3.

Is Viewpoint Molecular Targeting a funded company?

Viewpoint Molecular Targeting is a funded company, having raised a total of $14.3M across 12 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Oct 22, 2014.

When was the latest funding round of Viewpoint Molecular Targeting?

Viewpoint Molecular Targeting's latest funding was a $***** Grant (prize money) round on Sep 15, 2025, with participation from 1 investor. Its primary sector is Oncology. In United States, the Oncology sector has seen $3.87B in funding in 2026 to date.

Where does Viewpoint Molecular Targeting rank among its competitors?

Viewpoint Molecular Targeting ranks 1139th amongst 3343 active competitors, of which 1124 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Viewpoint Molecular Targeting?

Viewpoint Molecular Targeting's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Viewpoint Molecular Targeting - 2026 Company Profile, Team, Funding & Competitors

Company Details

Viewpoint Molecular Targeting is a US-based, early-stage pharma developing "theranostics" for metastatic melanoma and other cancers. Its lead product targets a cell surface receptor that is found on the cell surface of metastatic melanoma cells. They are developing image-guided therapies. The company has invented or licensed a portfolio of theranostics at the preclinical and clinical stage of development, with the lead agent starting Phase I human imaging of metastatic melanoma.

Website: viewpointmt.com
Social
Email ID: *****@viewpointmt.com
Registered Address: 2500 Crosspark Rd Coralville, IA 52241

Key Metrics

Founded Year

2008

Location

Coralville, United States

Stage

Series A

Total Funding

$14.3M in 12 rounds

Latest Funding Round

Grant (prize money), Sep 15, 2025, $*****

Investors

Next Level Ventures & 3 more

Ranked

1139^th among 3343 active competitors

Employee Count

3 as on Jul 31, 2026

Similar Companies

Jazz Pharmaceuticals & 2995 more

View Viewpoint Molecular Targeting's full profile

Viewpoint Molecular Targeting is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
VIEWPOINT MOLECULAR TARGETING, INC. CIN: 26-3526327 , United States, Active	Jan 28, 2018	-	29 (As on Dec 31, 2022)	-

Viewpoint Molecular Targeting has raised a total funding of $14.3M over 12 rounds. Its first funding round was on Oct 22, 2014. Its latest funding round was a Grant (prize money) round on Sep 15, 2025 for $*****. 1 investor participated in its latest round. Viewpoint Molecular Targeting has 4 institutional investors.

Here is the list of recent funding rounds of Viewpoint Molecular Targeting:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 15, 2025	5871089	Grant (prize money)	5449856	9990161	9848021	4642830
Jun 05, 2024	3687532	Grant (prize money)	7951967	2138865	6963103	HHS
Aug 04, 2022	1835373	Grant (prize money)	5207285	3878201	7841908	HHS

Access funding benchmarks and valuations. Sign up today!

View details of Viewpoint Molecular Targeting's funding rounds and investors

The founders of Viewpoint Molecular Targeting are Michael Schultz and Frances Johnson.

Here are the details of Viewpoint Molecular Targeting's key team members:

Michael Schultz: Founder of Viewpoint Molecular Targeting. They serve on the board of 1 company.
Frances Johnson: Founder of Viewpoint Molecular Targeting.

View details of Viewpoint Molecular Targeting's Founder profiles and Board Members

Viewpoint Molecular Targeting's employee count trend

Viewpoint Molecular Targeting has 3 employees as of Jul 26. Here is Viewpoint Molecular Targeting's employee count trend over the years:

Employee count trend for Viewpoint Molecular Targeting

Uncover Viewpoint Molecular Targeting's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Viewpoint Molecular Targeting include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Viewpoint Molecular Targeting, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, Leaps by Bayer & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
1139th	Viewpoint Molecular Targeting 2008, Coralville (United States), Series A	US-based, early-stage pharma developing "theranostics" for metastatic melanoma	$14.3M	Next Level Ventures, Lowa Seed Fund & 2 others	39/100